TENAYA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.56 USD | +0.44% |
|
+5.02% | +41.98% |
| 03-20 | Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating | MT |
| 03-19 | North American Morning Briefing : Stock Futures -2- | DJ |
| Sales 2024 * | 833K 66.73M | Sales 2025 * | 4.6M 368M | Capitalization | 356M 28.54B |
|---|---|---|---|---|---|
| Net income 2024 * | -136M -10.89B | Net income 2025 * | -151M -12.09B | EV / Sales 2024 * | 352 x |
| Net cash position 2024 * | 63.39M 5.08B | Net cash position 2025 * | 52.05M 4.17B | EV / Sales 2025 * | 66.2 x |
| P/E ratio 2024 * |
-2.63
x | P/E ratio 2025 * |
-2.56
x | Employees | 140 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Tenaya Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.44% | ||
| 1 week | +5.02% | ||
| Current month | +1.32% | ||
| 1 month | -7.82% | ||
| 3 months | -3.16% | ||
| 6 months | +148.65% | ||
| Current year | +41.98% |
1 week
3.97
4.72
1 month
3.975.10
Current year
2.747.01
1 year
1.668.09
3 years
1.6432.00
5 years
1.6432.00
10 years
1.6432.00
| Managers | Title | Age | Since |
|---|---|---|---|
Faraz Ali
CEO | Chief Executive Officer | 51 | 31/05/18 |
Leone Patterson
DFI | Director of Finance/CFO | 61 | 31/05/21 |
Kee-Hong Kim
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Williams
BRD | Director/Board Member | 75 | 30/09/16 |
David Goeddel
CHM | Chairman | 72 | 31/07/16 |
Jeffrey Walsh
BRD | Director/Board Member | 58 | 29/02/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +1.27% | - | |
| 0.00% | 18 M€ | +2.36% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 4.6 | +1.32% | 13 755 |
| 30/04/24 | 4.54 | 0.00% | 171,204 |
| 29/04/24 | 4.54 | +5.34% | 157,709 |
| 26/04/24 | 4.31 | +2.13% | 100,974 |
| 25/04/24 | 4.22 | -3.65% | 384,566 |
Delayed Quote Nasdaq, May 01, 2024 at 03:27 pm
More quotes
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Companyâs advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Companyâs adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.54
USD
Average target price
19.43
USD
Spread / Average Target
+327.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.98% | 356M | |
| -0.34% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.00% | 24.63B | |
| -23.47% | 18.2B | |
| +26.62% | 12.01B | |
| -4.02% | 11.76B | |
| +12.78% | 10.4B | |
| -4.11% | 9.94B |
- Stock Market
- Equities
- TNYA Stock
